An early look at selective RET inhibitor resistance: new challenges and opportunities.

Lin, Jessica J; Gainor, Justin F

Lin, Jessica J; Gainor, Justin F.

Affiliation

Lin JJ; Center for Thoracic Cancers, Department of Medicine, Massachusetts General Hospital Cancer Center, Boston, MA, USA.
Gainor JF; Center for Thoracic Cancers, Department of Medicine, Massachusetts General Hospital Cancer Center, Boston, MA, USA. jgainor@partners.org.

Br J Cancer ; 124(11): 1757-1758, 2021 05.

Article in En | MEDLINE | ID: mdl-33758332

ABSTRACT

Two RET inhibitors, selpercatinib and pralsetinib, recently received approval for the treatment of advanced RET fusion-positive lung cancer. Acquired resistance to these inhibitors will be a major challenge. We have shown that resistance can emerge due to recurrent RET kinase domain mutations and, in most cases, due to RET-independent mechanisms.

Subject(s)

Drug Resistance, Neoplasm; Protein Kinase Inhibitors/therapeutic use; Proto-Oncogene Proteins c-ret/antagonists & inhibitors; Carcinoma, Non-Small-Cell Lung/drug therapy; Carcinoma, Non-Small-Cell Lung/genetics; Carcinoma, Non-Small-Cell Lung/pathology; Drug Resistance, Neoplasm/genetics; Humans; Lung Neoplasms/drug therapy; Lung Neoplasms/genetics; Lung Neoplasms/pathology; Medical Oncology/methods; Medical Oncology/trends; Molecular Targeted Therapy/methods; Molecular Targeted Therapy/standards; Molecular Targeted Therapy/trends; Mutation; Proto-Oncogene Proteins c-ret/genetics

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Drug Resistance, Neoplasm / Protein Kinase Inhibitors / Proto-Oncogene Proteins c-ret Limits: Humans Language: En Journal: Br J Cancer Year: 2021 Type: Article Affiliation country: United States

Fulltext

XML

PubMed Links

Search on Google